Cargando…

The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens

Multiple myeloma (MM) is a hematological malignancy characterized by the clonal proliferation of plasma cells in the bone marrow (BM) microenvironment. Despite the progress made in treatment, some MM patients still die within the first year of diagnosis. Numerous studies investigating microRNA (miRN...

Descripción completa

Detalles Bibliográficos
Autores principales:	Puła, Anna, Robak, Paweł, Jarych, Dariusz, Mikulski, Damian, Misiewicz, Małgorzata, Drozdz, Izabela, Fendler, Wojciech, Szemraj, Janusz, Robak, Tadeusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9917942/ https://www.ncbi.nlm.nih.gov/pubmed/36769265 http://dx.doi.org/10.3390/ijms24032938

Ejemplares similares

Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
por: Robak, Paweł, et al.
Publicado: (2021)

Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib
por: Robak, Paweł, et al.
Publicado: (2020)

Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib
por: Mikulski, Damian, et al.
Publicado: (2021)

The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients
por: Robak, Paweł, et al.
Publicado: (2020)

The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib
por: Robak, Pawel, et al.
Publicado: (2021)

P868: A CIRCULATING SERUM MIRNAS-BASED MODEL TO PREDICT EARLY MORTALITY IN MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-BASED REGIMENS.
por: Puła, A., et al.
Publicado: (2022)

The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications
por: Puła, Anna, et al.
Publicado: (2021)

Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study
por: Mikulski, Damian, et al.
Publicado: (2022)

Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
por: Robak, Pawel, et al.
Publicado: (2019)

High serum miR-223-3p expression level predicts complete response and prolonged overall survival in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation
por: Mikulski, Damian, et al.
Publicado: (2023)

Dose and drug changes in chronic lymphocytic leukemia cell response in vitro: A comparison of standard therapy regimens with two novel cyclin-dependent kinase inhibitors
por: Kubczak, Małgorzata, et al.
Publicado: (2019)

PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives
por: Hus, Iwona, et al.
Publicado: (2022)

Editorial: Novel targeted drugs for indolent lymphoid malignancies
por: Robak, Tadeusz, et al.
Publicado: (2023)

Measurable residual disease in hairy cell leukemia: Technical considerations and clinical significance
por: Robak, Tadeusz, et al.
Publicado: (2022)

High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
por: Urbańska-Ryś, Halina, et al.
Publicado: (2003)

The selected genetic polymorphisms of metalloproteinases MMP2, 7, 9 and MMP inhibitor TIMP2 in sarcoidosis
por: Piotrowski, Wojciech J., et al.
Publicado: (2011)

Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases
por: Robak, Tadeusz, et al.
Publicado: (2009)

Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
por: Robak, Ewa, et al.
Publicado: (2022)

Exhaled IL-8 in Systemic Lupus Erythematosus with and without Pulmonary Fibrosis
por: Nielepkowicz-Goździńska, Agnieszka, et al.
Publicado: (2014)

Leukemia Cutis—The Current View on Pathogenesis, Diagnosis, and Treatment
por: Robak, Ewa, et al.
Publicado: (2023)

The Choice of Regimens Based on Bortezomib for Patients with Newly Diagnosed Multiple Myeloma
por: He, Jingsong, et al.
Publicado: (2014)

Relationship between bortezomib-containing regimens and the incidence of tuberculosis in patients with myeloma
por: Kim, Kihyun, et al.
Publicado: (2013)

Cardiac Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
por: Robak, Tadeusz, et al.
Publicado: (2022)

Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus.
por: Robak, Ewa, et al.
Publicado: (2003)

Skin changes in hairy cell leukemia
por: Robak, Ewa, et al.
Publicado: (2020)

Application of New Drugs in Chronic Lymphocytic Leukemia
por: Robak, Tadeusz
Publicado: (2010)

Book review: Safety of Biologics Therapy
por: Robak, Tadeusz
Publicado: (2017)

Personalized therapy tests for the monitoring of chronic lymphocytic leukemia development
por: Rogalińska, Małgorzata, et al.
Publicado: (2017)

Long-term outcomes of different bortezomib-based regimens in Chinese myeloma patients
por: Wang, Hua, et al.
Publicado: (2016)

Selinexor, Bortezomib and Dexamethasone: An Effective Salvage Regimen for Heavily Pretreated Myeloma Patients
por: Delforge, Michel, et al.
Publicado: (2022)

Atypical Chronic Lymphocytic Leukemia—The Current Status
por: Robak, Tadeusz, et al.
Publicado: (2023)

Extracellular Vesicles in Multiple Myeloma—Cracking the Code to a Better Understanding of the Disease
por: Iskrzak, Justyna, et al.
Publicado: (2022)

Artificial microenvironment of in vitro glioblastoma cell cultures changes profile of miRNAs related to tumor drug resistance
por: Witusik-Perkowska, Monika, et al.
Publicado: (2019)

Bortezomib and melphalan as a conditioning regimen for autologous stem cell transplantation in multiple myeloma
por: Lee, Se Ryeon, et al.
Publicado: (2010)

Exonic variants in multiple myeloma patients associated with relapsed/ refractory and response to bortezomib regimens
por: Kakoo, Ashraf, et al.
Publicado: (2022)

Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma
por: Robak, Marta, et al.
Publicado: (2012)

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
por: Richardson, Paul G., et al.
Publicado: (2021)

Efficiency and Tolerability of Induction and Consolidation Therapy with Arsenic Trioxide/Bortezomib/Ascorbic Acid/Dexamethasone (ABCD) Regimen Compared to Bortezomib/Dexamethasone (BD) Regimen in Newly Diagnosed Myeloma Patients
por: Qian, Wensi, et al.
Publicado: (2020)

Bortezomib-induced painful neuropathy in patients with multiple myeloma
por: Bilińska, Małgorzata, et al.
Publicado: (2013)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_b7cpankcsnt8q31i186v3erfo9